IP implications of the FDA guidance for use of AI in drug development By Dr Rose Hughes on Tuesday, June 17, 2025 Artificial Intelligence FDA ip strategy patents PatKat pharma ip Rose Hughes +
[Guest post] Covid-19 Treatments: The Issue of Orphan Drug Status and Patents By Frantzeska Papadopoulou on Friday, April 03, 2020 COVID-19 EMA FDA Frantzeska Papadopoulou Guest post orphan drugs patents +
When "mayo" is not mayonnaise, yet still is mayonnnaise: All a matter of the label? By Neil Wilkof on Sunday, August 20, 2017 FDA Hampton Creek Just Mayo manyonnaise Mayo Neil Wilkof Unilever +
Allergan v Sandoz: when obvious is not obvious enough! By Stefano Barazza on Tuesday, May 07, 2013 Allergan v Sandoz Combigan court of appeals FDA federal circuit obviousness +